AstraZeneca PLC (AZN)vsSolventum Corp. (SOLV)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
SOLV
Solventum Corp.
$81.01
-1.71%
HEALTHCARE · Cap: $14.28B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 632% more annual revenue ($60.44B vs $8.26B). SOLV leads profitability with a 17.3% profit margin vs 17.2%. SOLV appears more attractively valued with a PEG of 1.22. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SOLV
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SOLV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 29 in profit
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Distress zone — elevated risk
Elevated debt levels
Revenue declined 3.0%
Earnings declined 91.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SOLV
The strongest argument for SOLV centers on P/E Ratio, Return on Equity, Price/Book. Profitability is solid with margins at 17.3% and operating margin at 5.6%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SOLV
The primary concerns for SOLV are Altman Z-Score, Debt/Equity, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while SOLV is a declining play — different risk/reward profiles.
SOLV carries more volatility with a beta of 0.75 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 60/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Solventum Corp.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?